CliffBio
small molecule

OPANA ER

OXYMORPHONE HYDROCHLORIDE

Loss of exclusivityNovember 2029latest FDA-listed patent expiry
CompanyEndo Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameOPANA ER
Active ingredientOXYMORPHONE HYDROCHLORIDE
Strength20MG
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2011
Marketing statusDISCN

Listed patents

PatentExpiresType
8871779November 2029substance
7851482July 2029substance
8808737June 2027use U-1598

More from Endo Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

OPANA ER patent cliff — loss of exclusivity November 2029 | CliffBio